Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from the final analysis of a Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast cancer. The data were presented in a poster session (Poster #1017) at the American Society of Clinical Oncology Meeting in Chicago, IL.
"Despite existing therapies, new and effective treatment options for patients with previously treated metastatic breast cancer are needed," said Joyce A. O'Shaughnessy, MD, a breast cancer specialist at Texas Oncology, Baylor Sammons Cancer Center, and US Oncology, and the principal investigator of the study. "In this study, PEG-SN38 resulted in a significant overall response rate in previously treated patients, as well as in triple negative breast cancer and platinum-resistant patients. These findings provide further clinical evidence indicating the potential of PEG-SN38 to deliver meaningful therapeutic benefit in patients with breast cancer."
The study was designed to evaluate the efficacy of single-agent PEG-SN38 in 164 female patients who had previously been treated for metastatic breast cancer with either anthracycline and taxane (AT, up to 2 prior lines of therapy) (n=81), or anthracycline, taxane and capecitabine (ATX, up to 4 prior lines of therapy) (n=83). The primary objective of the study was to determine overall response; secondary objectives included duration of response, progression-free survival (PFS), overall survival (OS) and safety.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.